蔡金赞,朱永翔,朱灏,张瑶俊

• 1:南京医科大学附属南京医院心血管内科
• 2:徐州市第三人民医院心血管内科

摘要(Abstract)：

<正>经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后出现支架内再狭窄(in-stent restenosis,ISR)已成为冠心病介入领域的一个难题。ISR首选治疗方式主要为药物洗脱球囊(drug-eluting balloon,DCB)和新一代药物洗脱支架(drug-eluting stent,DES),但两者均存在着各自的局限,且再次发生ISR的风险仍会很高。生物可吸收支架(bioresorbable scaff old,BRS)作为冠状动脉介入治疗领域的第四次变革,或许能给ISR患者带来崭新的治疗策略。本文将主要介绍ISR病变的治疗现状、BRS在ISR病变中的应用探索、腔内影像学技术指导BRS治疗ISR病变及未来展望。

关键词(KeyWords)： 生物可吸收支架;支架内再狭窄;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 南京市科技计划项目(201503024);; 南京市医学科技发展资金资助项目(YKK15100);; 江苏省青年医学人才(QNRC2016065);; 江苏省六大人才高峰项目(WSN-219)

作者(Author): 蔡金赞,朱永翔,朱灏,张瑶俊

参考文献(References)：

• [1]Byrne RA,Joner M,Kastrati A.Stent thrombosis and restenosis:what have we learned and where are we going?The Andreas Grüntzig Lecture ESC 2014.Eur Heart J,2015,36(47):3320-3331.
• [2]徐绍鹏,万征.第二代冠状动脉药物洗脱支架的临床预后研究.中国介入心脏病学杂志,2015,23(7):399-402.
• [3]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2015》概要.中国循环杂志,2016,28(6):521-528.
• [4]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [5]Alfonso F,Byrne RA,Rivero F,et al.Current treatment of in-stent restenosis.J Am Coll Cardiol,2014,63(24):2659-2673.
• [6]Ormiston JA,Serruys PW,Regar E,et al.A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions(ABSORB):a prospective open-label trial.Lancet,2008,371(9616):899-907.
• [7]Onuma Y,Serruys PW,Perkins LE,et al.Intracoronary optical coherence tomography and histology at 1 month and 2,3,and4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model:an attempt to decipher the human optical coherence tomography images in the ABSORB trial.Circulation,2010,122(22):2288-2300.
• [8]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaff old versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385(9962):43-54.
• [9]Haude M,Ince H,Abizaid A,et al.Safety and performance of the second-generation drug-eluting absorbable metal scaff old in patients with de-novo coronary artery lesions(BIOSOLVE-II):6 month results of a prospective,multicentre,non-randomised,fi rst-in-man trial.Lancet,2016,387(10013):31-39.
• [10]Grasso C,Attizzani GF,PatanéM,et al.First-in-human description of everolimus-eluting bioabsorbable vascular scaff old implantation for the treatment of drug-eluting stent failure:insights from optical coherence tomography.Int J Cardiol,2013,168(4):4490-4491.
• [11]Cadrin-Tourigny J,Dong L,Maehara A,et al.Bioresorbable vascular scaff old use in a case of in-stent restenosis.Arq Bras Cardiol,2014,103(1):e11-14.
• [12]Foin N,Lee R,Wong P,et al.Very late metallic stent malapposition and in-stent restenosis treated with a bioresorbable scaff old:a novel alternative for an old problem.Euro Intervention,2015,11(4):e1.
• [13]Camuglia AC,Lavi S.Bioresorbable vascular scaff old implantation for treatment of recurrent in-stent restenosis:insights from optical coherence tomography.Int J Cardiol,2014,172(1):238-239.
• [14]Jamshidi P,Nyff enegger T,Sabti Z,et al.A novel approach to treat in-stent restenosis:6-and 12-month results using the everolimus-eluting bioresorbable vascular scaff old.Euro Intervention,2016,11(13):1479-1486.
• [15]Mamuti W,Ablimit A,Kelimu W,et al.Comparison of drugeluting balloon versus drug-eluting stent in patients with instent restenosis:insight from randomized controlled trials.Int J Cardiol,2015,179:424-429.
• [16]Tamburino C,Latib A,van Geuns RJ,et al.Contemporary practice and technical aspects in coronary intervention with bioresorbable scaff olds:a European perspective.Euro Intervention,2015,11(1):45-52.
• [17]Moscarella E,Varricchio A,Stabile E,et al.Bioresorbable vascular scaff old implantation for the treatment of coronary instent restenosis:results from a multicenter Italian experience.Int J Cardiol,2015,199:366-372.
• [18]Suwannasom P,Sotomi Y,Ishibashi Y,et al.The Impact of Post-Procedural Asymmetry,Expansion,and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.JACC Cardiovasc Interv,2016,9(12):1231-1242.
• [19]Puricel S,Cuculi F,Weissner M,et al.Bioresorbable Coronary Scaffold Thrombosis:Multicenter Comprehensive Analysis of Clinical Presentation,Mechanisms,and Predictors.J Am Coll Cardiol,2016,67(8):921-931.
• [20]Tr?bs M,Achenbach S,R?ther J,et al.Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.Catheter Cardiovasc Interv,2016,88(6):872-880.
• [21]Capodanno D,Gori T,Nef H,et al.Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaf f olds in routine clinical practice:early and midterm outcomes from the European multicentre GHOST-EU registry.Euro Intervention,2015,10(10):1144-1153.
• [22]Rivero F,Bastante T,Cuesta J,et al.Treatment of in-stent restenosis with bioresorbable vascular scaff olds:optical coherence tomography insights.Can J Cardiol,2015,31(3):255-259.
• [23]Ali ZA,Maehara A,Généreux P,et al.Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation(ILUMIEN III:OPTIMIZE PCI):a randomised controlled trial.Lancet,2016,388(10060):2618-2628.
• [24]Caiazzo G,Longo G,Giavarini A,et al.Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaff olds.Int J Cardiol,2016,221:352-358.
• [25]Allahwala UK,Cockburn JA,Shaw E,et al.Clinical utility of optical coherence tomography(OCT)in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.Euro Intervention,2015,10(10):1154-1159.
• [26]Rivero F,Benedicto A,Bastante T,et al.Subacute thrombosis of a bioresorbable vascular scaff old implanted for recurrent instent restenosis.Euro Intervention,2015,11(7):780.
• [27]Otsuka F,Pacheco E,Perkins LE,et al.Long-term safety of an everolimus-eluting bioresorbable vascular scaff old and the cobaltchromium XIENCE V stent in a porcine coronary artery model.Circ Cardiovasc Interv,2014,7(3):330-342.
• [28]Karabulut A,Demirci Y.Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaff old in in-stent stenosis.Postepy Kardiol Interwencyjnej,2015,11(1):64-66.